Compare Stocks → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:BFRINASDAQ:BIVINASDAQ:CNTXNASDAQ:ELDNNASDAQ:GRTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRIBiofrontera$1.50+3.4%$1.35$0.61▼$13.42$7.35M0.83135,324 shs53,944 shsBIVIBioVie$0.49+2.1%$0.76$0.45▼$8.69$19.29M0.79879,248 shs686,715 shsCNTXContext Therapeutics$1.41+3.7%$1.23$0.47▼$1.69N/A2.1777,321 shs23,977 shsELDNEledon Pharmaceuticals$2.16+6.9%$1.79$1.07▼$2.95$50.12M0.87115,702 shs189,922 shsGRTXGalera Therapeutics$0.19$0.20$0.09▼$3.59$10.38M2.173.33 million shs352,721 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRIBiofrontera+3.81%-17.13%+25.00%-3.85%-86.89%BIVIBioVie+1.78%+0.78%-14.56%-45.96%-93.66%CNTXContext Therapeutics+3.68%-3.42%+21.03%+48.42%+141.40%ELDNEledon Pharmaceuticals+6.93%+35.00%+7.46%+20.00%-4.85%GRTXGalera Therapeutics+1.68%+14.12%-17.09%+7.48%-93.10%Elon Musk’s Controversial New Project: “Apollo” (Ad)Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...Click here to see the details because there's a lot of money at stake.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRIBiofrontera2.4348 of 5 stars3.55.00.00.01.10.01.3BIVIBioVie1.4009 of 5 stars3.34.00.00.02.40.00.0CNTXContext Therapeutics2.7114 of 5 stars3.55.00.00.03.20.00.6ELDNEledon Pharmaceuticals2.3245 of 5 stars3.53.00.00.01.11.71.3GRTXGalera TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRIBiofrontera3.00Buy$18.001,100.00% UpsideBIVIBioVie2.50Moderate Buy$8.001,526.68% UpsideCNTXContext Therapeutics3.00Buy$4.00183.69% UpsideELDNEledon Pharmaceuticals3.00Buy$10.67393.83% UpsideGRTXGalera Therapeutics1.75ReduceN/AN/ACurrent Analyst RatingsLatest BFRI, BIVI, ELDN, CNTX, and GRTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2024ELDNEledon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$13.003/21/2024CNTXContext TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRIBiofrontera$34.07M0.22N/AN/A$3.16 per share0.47BIVIBioVieN/AN/AN/AN/A$0.42 per shareN/ACNTXContext TherapeuticsN/AN/AN/AN/A$0.74 per shareN/AELDNEledon PharmaceuticalsN/AN/AN/AN/A$3.45 per shareN/AGRTXGalera TherapeuticsN/AN/AN/AN/A($2.41) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRIBiofrontera-$20.13M-$15.82N/AN/AN/A-59.09%-344.98%-72.85%5/10/2024 (Estimated)BIVIBioVie-$50.26M-$1.17N/A∞N/AN/A-332.18%-137.85%5/10/2024 (Estimated)CNTXContext Therapeutics-$23.96M-$1.50N/AN/AN/AN/A-115.50%-97.04%5/8/2024 (Estimated)ELDNEledon Pharmaceuticals-$40.33M-$1.79N/AN/AN/AN/A-46.15%-43.10%5/9/2024 (Estimated)GRTXGalera Therapeutics-$59.08M-$1.41N/A∞N/AN/AN/A-137.47%5/9/2024 (Estimated)Latest BFRI, BIVI, ELDN, CNTX, and GRTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023ELDNEledon Pharmaceuticals-$0.38-$0.29+$0.09-$0.29N/AN/A3/28/2024Q4 2023GRTXGalera TherapeuticsN/A-$0.10-$0.10-$0.10N/AN/A3/21/2024Q4 2023CNTXContext Therapeutics-$0.35-$0.42-$0.07-$0.42N/AN/A3/15/2024Q4 2023BFRIBiofronteraN/A-$2.33-$2.33-$6.31N/A$10.60 million2/12/2024Q2 2024BIVIBioVie-$0.32-$0.22+$0.10-$0.22N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRIBiofronteraN/AN/AN/AN/AN/ABIVIBioVieN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/AELDNEledon PharmaceuticalsN/AN/AN/AN/AN/AGRTXGalera TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRIBiofronteraN/A1.280.67BIVIBioVieN/A1.471.47CNTXContext TherapeuticsN/A3.833.83ELDNEledon PharmaceuticalsN/A14.4114.41GRTXGalera TherapeuticsN/A4.364.36OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRIBiofrontera10.08%BIVIBioVie4.59%CNTXContext Therapeutics14.03%ELDNEledon Pharmaceuticals56.77%GRTXGalera Therapeutics50.77%Insider OwnershipCompanyInsider OwnershipBFRIBiofrontera0.21%BIVIBioVie4.80%CNTXContext Therapeutics9.38%ELDNEledon Pharmaceuticals19.40%GRTXGalera Therapeutics6.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableBFRIBiofrontera835.09 million5.08 millionNo DataBIVIBioVie1839.92 million38.01 millionOptionableCNTXContext Therapeutics5N/AN/ANot OptionableELDNEledon Pharmaceuticals1724.81 million20.00 millionOptionableGRTXGalera Therapeutics754.39 million50.64 millionOptionableBFRI, BIVI, ELDN, CNTX, and GRTX HeadlinesSourceHeadlineGalera Therapeutics (NASDAQ:GRTX) Trading Down 3.8%americanbankingnews.com - April 16 at 1:48 AMGalera Therapeutics Seeks Strategic Alternatives Amid Financial Setbacks and Regulatory Challengesmsn.com - April 1 at 5:26 AMGalera Therapeutics: Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updatesfinanznachrichten.de - March 28 at 2:09 PMGalera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updatesglobenewswire.com - March 28 at 7:00 AMGRTX Apr 2024 0.500 callfinance.yahoo.com - March 16 at 9:07 AMGalera Therapeutics, Inc. (GRTX)nz.finance.yahoo.com - March 12 at 5:23 PMGalera Therapeutics, Inc.edition.cnn.com - February 27 at 7:25 AMGalera Therapeutics Inc (GRTX)investing.com - February 4 at 12:37 AMGalera Therapeutics Stock (NASDAQ:GRTX) Dividends: History, Yield and Datesbenzinga.com - February 4 at 12:37 AMGalera Therapeutics Insiders Lose Out As Stock Sinks To US$0.17finance.yahoo.com - January 21 at 2:16 PMLocal publicly traded stocks lag far behind national indices in 2023bizjournals.com - January 16 at 1:33 PMDow Tumbles Over 200 Points; US Trade Gap Narrows In Novembermsn.com - January 9 at 2:28 PMGalera Therapeutics (GRTX) Price Target Increased by 7.14% to 0.38msn.com - November 28 at 2:59 AMGalera Therapeutics: Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updatesfinanznachrichten.de - November 14 at 8:41 AMGalera Therapeutics: Q3 Earnings Insightsbenzinga.com - November 14 at 8:41 AMGalera Reports Third Quarter 2023 Financial Results and Recent Corporate Updatesfinance.yahoo.com - November 14 at 8:41 AMGalera Therapeutics's Earnings Outlookbenzinga.com - November 13 at 2:56 PMUnderstanding the Risks of Investing in Galera Therapeutics Inc (GRTX)knoxdaily.com - November 8 at 7:21 AMUS Stocks Fall; Pfizer Swings To Q3 Lossbenzinga.com - November 1 at 5:19 PMGalera Therapeutics Inc (GRTX) rating downgrades by Piper Sandlerknoxdaily.com - November 1 at 5:19 PMDow Gains 50 Points; Global Payments Posts Upbeat Earningsbenzinga.com - October 31 at 3:16 PMGalera Therapeutics warns of potential shutdown as it halts clinical trials and stock tanksbizjournals.com - October 31 at 3:16 PMWhy Is Cancer Focused Galera Therapeutics Stock Sinking Today?msn.com - October 31 at 3:16 PMGalera plunges after citing risks to business continuitymsn.com - October 31 at 3:16 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsBiofronteraNASDAQ:BFRIBiofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.BioVieNASDAQ:BIVIBioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.Context TherapeuticsNASDAQ:CNTXContext Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Eledon PharmaceuticalsNASDAQ:ELDNEledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Galera TherapeuticsNASDAQ:GRTXGalera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also developing GC4711, a dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is based in Malvern, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.